Myocardial angiogenesis induction with bone protein derived growth factors (animal experiment).
Myocardial angiogenesis induction with vascular growth factors constitutes a potential strategy for patients whose coronary artery disease is refractory to conventional treatment. The importance of angiogenesis in bone formation has led to the development of growth factors derived from bovine bone protein. Twelve pigs (mean weight, 73 +/- 3 kg) were chosen for the study. In the first group (n = 6, growth factor group) five 100 micrograms boluses of growth factors derived from bovine bone protein, diluted in Povidone 5%, were injected in the lateral wall of the left ventricle. In the second group (n = 6, control group), the same operation was performed but only the diluting agent was injected. All the animals were sacrificed after 28 days and the vascular density of the left lateral wall (expressed as the number of vascular structures per mm2) as well as the area of blood vessel profiles per myocardial area analysed were determined histologically with a computerised system. The growth factor group had a capillary density which was significantly higher than that of the control group: 12.6 +/- 0.9/mm2 vs 4.8 +/- 0.5/mm2 (p < 0.01). The same holds true for the arteriolar density: 1 +/- 0.2/mm2 vs 0.3 +/- 0.1/mm2 (p < 0.01). The surface ratios of blood vessel profiles per myocardial area were 4900 +/- 800 micron 2/mm2 and 1550 +/- 400 micron 2/mm2 (p < 0.01) respectively. In this experimental model, bovine bone protein derived growth factors induce a significant neovascularisation in healthy myocardium, and appear therefore as promising candidates for therapeutic angiogenesis.
Mueller
X M
XM
Service de chirurgie cardiovasculaire, CHUV (Centre Hospitalier Universitaire Vaudois), Lausanne, Switzerland. xavier.mueller@chuv.hospvd.ch
Tevaearai
H T
HT
Genton
C Y
CY
Chaubert
P
P
von Segesser
L K
LK
D000818:Animals; D001842:Bone and Bones / Q000737:chemistry*; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology*; D003331:Coronary Vessels / Q000187:drug effects / Q000502:physiology*; D005169:Factor VIII / Q000032:analysis; D006133:Growth Substances / Q000302:isolation & purification / Q000494:pharmacology*; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D011205:Povidone; D011506:Proteins / Q000302:isolation & purification / Q000494:pharmacology*; D013552:Swine
D006133:Growth Substances; D011506:Proteins; D005169:Factor VIII; D011205:Povidone